Nasdaq
$2.11▼ 0.24%vs prev close
🔒 Quotes & buy pressure are MAX onlySee plans
Market cap $410.3MShares out 1.900M sh
Chart
Filings & news by date
Hover (PC) or tap (mobile) a candle to see that day only
Filings
11- 10.5After-hours26.10.06 05:104Ownership#●●●
Altimmune, Inc.
Insider Christophe Arbet-Engels of Altimmune, Inc. filed a Form 4 report regarding changes in beneficial ownership of securities as of October 1, 2026. This filing details the specific equity transactions conducted by the reporting insider.…more
$2.11-0.24%vs prev closeDetected5m · 30m · 60m · Next dayPLUSView filingShare
- 10.5After-hours26.10.06 05:054Ownership
Altimmune, Inc.
Altimmune executive Gregory L. Weaver filed a Form 4 report on October 5, 2026, disclosing changes in his beneficial ownership of company securities as of October 1, 2026. This filing formalizes the adjustment in the executive's equity holdings.…more
$2.11-0.24%vs prev closeView filingShare - 10.2After-hours26.10.03 05:174Ownership
Altimmune, Inc.
Insider Richard Thomas Menziuso of Altimmune, Inc. has filed a Form 4 to report changes in his beneficial ownership of securities. This filing serves as an official disclosure of the insider's equity position to the SEC.…more
$2.11-0.24%vs prev closeView filingShare
10 more filings
Sign up free to unlock the full feed and real-time filing & news alerts.
- ✓Free — no card required
- ✓Full real-time filing & news feed
- ✓Daily Today Report
News
GlobeNewswire- 9.23Pre-market26.09.23 21:00#●●●#●●●
Altimmune to Participate in Stifel Cardiometabolic Forum
Altimmune announced that its management will participate in a fireside chat at the upcoming Stifel Cardiometabolic Forum. This event is a routine investor relations activity and does not provide new material financial catalysts.…more
$2.11-0.24%vs prev closeDetected5m · 30m · 60m · Next dayPLUS
- 9.3Pre-market26.09.03 21:00
●●●●●●●● ●●●●● ●●●●●●
Altimmune management will participate in a fireside chat at the 21st Annual Wells Fargo Healthcare Conference on September 10. This event is a standard investor relations activity and does not provide new material financial catalysts.…more
$2.11-0.24%vs prev close - 8.12Pre-market26.08.12 20:30
●●●●●●●● ●●●●● ●●●●●●
Altimmune announced significant milestones including the initiation of its Phase 3 MASH trial and positive Phase 2 results for its AUD program. The company maintains a strong financial position with $519 million in cash to support its ongoing liver disease clinical programs.…more
$2.11-0.24%vs prev close
2 more news items
Sign up free to unlock the full feed and real-time filing & news alerts.
- ✓Free — no card required
- ✓Full real-time filing & news feed
- ✓Daily Today Report